Yin-Yang Balance of ACE/ACE2 Pathways: The Rational for ACE2 Pathway Inhibitor Administration in SARS-CoV-2 Patients

Loris Zamai

doi:10.20944/preprints202003.0338.v1

Submitted:

19 March 2020

Posted:

23 March 2020

Read the latest preprint version here

Part of the Following Collection

Preprints on COVID-19 and SARS-CoV-2

Subscription

Notify me about updates to this article or when a peer-reviewed version is published.

Preprint

Brief Report

This version is not peer-reviewed.

Yin-Yang Balance of ACE/ACE2 Pathways: The Rational for ACE2 Pathway Inhibitor Administration in SARS-CoV-2 Patients

Loris Zamai^*

A peer-reviewed article of this preprint also exists.

Submitted:

19 March 2020

Posted:

23 March 2020

Read the latest preprint version here

Part of the Following Collection

Preprints on COVID-19 and SARS-CoV-2

Abstract

The article describes the rational for inhibition of the angiotensin-converting enzyme 2 (ACE2) pathways as specific targets in patients infected by SARS-CoV-2.

Keywords:

Severe Acute Respiratory Syndrome Coronavirus-2

;

(soluble) ACE2

;

eosinophil

;

asthma

;

IL-10

;

IL-6

;

Lung fibrosis

;

Ang (1-7)

;

hypoxia

;

infarction

;

hypertension

Subject:

Medicine and Pharmacology - Pulmonary and Respiratory Medicine

Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.